Exploring the Potential of Ozempic-like Drugs for Migraine Relief

New findings suggest that drugs similar to Ozempic—commonly used for type 2 diabetes and obesity—might also be effective in treating migraines, even if they don’t lead to weight loss. A preliminary study published in the journal Headache and shared at the European Academy of Neurology (EAN) conference indicates that liraglutide, a medication for obesity and diabetes, significantly reduced the number of days patients suffered from severe migraines.

Liraglutide is part of a class known as GLP-1 agonists, which includes semaglutide, the active ingredient in Ozempic and Wegovy for weight loss. However, the researchers encourage caution regarding these exciting initial results. Dr. Alex Sinclair, a neurologist at the University of Birmingham, noted that the trial was small and lacked a comparison group that didn’t take the medication.

“It’s a fascinating study because it opens up new avenues for migraine treatment,” Sinclair commented. “But it’s still in the preliminary stages.”

This study could offer a novel option for patients with chronic migraines, especially those who haven’t found relief with existing treatments, remarked Dr. Chia-Chun Chiang from the Mayo Clinic, who wasn’t part of the research.

Significant Reduction in Migraine Days

Dr. Simone Braca from the University of Naples and her team administered liraglutide to 31 patients suffering from obesity and frequent migraines. The treatment began with 0.6 milligrams daily for a week, then increased to 1.2 mg daily for 11 weeks. After this period, almost half of the participants reported a reduction in headache days per month, dropping from an average of 20 to nine.

Seven patients experienced a remarkable 75% reduction in headache days, and one individual reported complete relief from migraines. Notably, weight loss did not occur during the study, which suggests that the improvement in migraine symptoms was not linked to shedding pounds. This is significant since obesity is known to increase the risk of severe headaches.

Braca pointed out that participants were selected because they didn’t respond to other migraine treatments, particularly those targeting CGRP, a molecule associated with migraine pain.

While the authors of the study proposed several theories about how liraglutide works, they did not gather definitive evidence for a specific mechanism. One hypothesis is that GLP-1 drugs might reduce intracranial pressure by decreasing cerebrospinal fluid production. This could potentially lead to lower CGRP levels, which are often linked to migraine exacerbation.

Braca referenced an earlier study led by Sinclair that indicated exenatide, another GLP-1 drug, could lower brain pressure and might also reduce migraine days, albeit without capturing a strong statistical difference.

Other suggested mechanisms include the possibility that liraglutide impacts CGRP release directly or regulates glucose metabolism, which has been implicated in migraine-related issues, according to Chiang.

Nevertheless, Sinclair emphasized several important limitations of the current study: its small size and brief duration, as well as the absence of a placebo group. The placebo effect—whereby participant symptoms improve due to believing they’re receiving treatment—can be quite pronounced in headache research.